With Celgene Acquisition Closed, Bristol Faces Major Milestones

Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue. 

Business teamwork puzzle pieces.
The $76bn merger adds significantly to Bristol's late-stage R&D pipeline. • Source: Shutterstock

More from Deals

More from Business